98%
921
2 minutes
20
Background: Despite advances in technology, patients with Cardiogenic Shock (CS) presenting with ST-segment myocardial infarction (STEMI) still have a poor prognosis with high mortality rates. A large proportion of these patients have multi-vessel coronary artery disease, the treatment of which is still unclear. We aimed to assess the trends in management of CS patients with multi-vessel disease (MVD), particularly looking at the incidence and outcomes of complete revascularisation compared to culprit vessel only.
Methods And Results: We undertook an observational cohort study of 21,210 STEMI patients treated between 2005 and 2015 at the 8 Heart Attack Centres in London, UK. Patients' details were recorded prospectively into local databases using the British Cardiac Intervention Society (BCIS) PCI dataset. 1058 patients presented with CS and MVD. Primary outcome was all-cause mortality. Patients were followed-up for a median of 4.1 years (IQR range: 2.2-5.8 years). 497 (47.0%) patients underwent complete revascularisation during primary PCI for CS with stable rates seen over time. These patients were more likely to be male, hypertensive and more likely to have poor LV function compared to the culprit vessel intervention group. Although crude, in hospital major adverse cardiac events (MACE) rates were similar (40.8% vs. 36.0%, p = 0.558) between the two groups. Kaplan-Meier analysis demonstrated no significant differences in mortality rates between the two groups (53.8% complete revascularisation vs. 46.8% culprit vessel intervention, p = 0.252) during the follow-up period. After multivariate cox analysis (HR 0.69 95% CI (0.44-0.98)) and the use of propensity matching (HR: 0.81 95% CI: 0.62-0.97) complete revascularisation was associated with reduced mortality. A number of co-variates were included in the model, including age, gender, diabetes, hypertension, hypercholesterolaemia, previous PCI, previous MI, chronic renal failure, Anterior infarct, number of treated vessels, pre-procedure TIMI flow, procedural success and GP IIb/IIIA use.
Conclusion: In a contemporary observational series of CS patients with MVD, complete revascularisation appears to be associated with better outcomes compared to culprit vessel only intervention. This supports on-going clinical trials in this area and provides further evidence of the association of complete revascularisation in STEMI with good outcomes.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.carrev.2019.06.007 | DOI Listing |
Orthop Traumatol Surg Res
September 2025
Service de Chirurgie Orthopédique Pédiatrique, Hôpital Universitaire Robert-Debré, Assistance Publique-Hôpitaux de Paris (AP-HP), Université de Paris, 48 Boulevard Sérurier, 75019 Paris, France.
Sickle cell disease is the most common serious genetic disease in the world. It is a systemic disease, characterized by vaso-occlusive phenomena, especially in the bone capillary network. Orthopedic complications are thus the most common, with a strong impact on quality of life.
View Article and Find Full Text PDFEur J Vasc Endovasc Surg
September 2025
Department of Epidemiology, Maastricht University, Maastricht, the Netherlands. Electronic address:
Objective: The current selection of patients for carotid revascularisation is mainly based on neurological symptoms and the degree of carotid artery stenosis. Individualised MRI based PRediction scOre using plaque Vulnerability for symptomatic carotid artEry disease patients (IMPROVE) can identify high risk patients who may benefit from carotid revascularisation, based on intraplaque haemorrhage, stenosis severity, cerebral symptoms, sex, and age. For use in clinical trials and eventual practice, the decision rule must be acceptable to clinicians.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
September 2025
Department of Anesthesiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
Background: Diabetic foot ulcers (DFU) are a prevalent complication of diabetes, leading to significant morbidity, mortality, and amputation rates. Chronic non-healing DFU often result from peripheral neuropathy, microvascular issues, and infection, with poor blood and oxygen supply being critical factors in delayed healing. The development of new treatments to promote blood supply and accelerate ulcer healing is a significant area of research for DFU management.
View Article and Find Full Text PDFVasc Health Risk Manag
September 2025
Department of Cardiology and Vascular Medicine, Universitas Padjadjaran/Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Introduction: Ischemic cardiomyopathy is the leading cause of heart failure and associated with increased morbidity and mortality. The role of percutaneous coronary intervention (PCI) in term of increasing survival and cardiovascular outcomes in ischemic cardiomyopathy remains unclear.
Purpose: To evaluate whether revascularization is associated with 30-day survival in ischemic cardiomyopathy in Dr.
Medicine (Baltimore)
September 2025
Division of Vascular Surgery, Department of Cardiovascular Surgery, Institute of Science Tokyo, Tokyo, Japan.
Rationale: Polycythemia vera (PV) is a type of myeloproliferative disorder, and thrombosis is one of its important complications. Arterial thrombosis commonly occurs in the coronary and cerebral arteries; however, reports of thrombosis in other arteries are limited, and it is even rarer in visceral arteries.
Patient Concerns: A 50-year-old woman with PV presented with anorexia and epigastric pain.